Takeda gave biopharma’s M&A bill a big boost in 2018 but to see just how slow the year was, take a look at deal volumes.
The takeovers of Loxo and Celgene put M&A back on the agenda, and positive clinical readouts from Sage and Axsome add to the celebratory mood.
Despite several changes of direction SAGE-217 comes out positive in postpartum depression, setting Sage Therapeutics up as a takeover target.
Deal adds a marketed small molecule and three pipeline agents, although Lilly will share revenue from Vitrakvi and LOXO-195 with Bayer.
Vantage has today published a detailed report into first-line lung cancer, discussing key upcoming trial readouts and regulatory decisions, and putting into context the…
Bayer tests what the market will bear for its newly approved therapy for cancers with NTRK mutations.
Amid market volatility, biotech’s best friend comes through once again: the FDA has authorised a bumper 53 new medicines so far in 2018 and several more are expected…
Pain drugs look like they could face different outcomes, while targeted cancer agents will have a big month. Two biosimilar decisions also await.
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.